1887

Abstract

is a critical priority pathogen listed by the World Health Organization due to increasing levels of resistance to carbapenem classes of antibiotics. It causes wound and other nosocomial infections, which can be life-threatening. Hence, there is an urgent need for the development of new classes of antibiotics.

To study the interaction of carabapenems with class D beta-lactamases (oxacillinases) and analyse drug resistance by studying enzyme–substrate complexes using modelling approaches as a means of establishing correlations with the phenotypic data.

The three-dimensional structures of carbapenems (doripenem, ertapenem, imipenem and meropenem) were obtained from DrugBank and screened against class D beta-lactamases. Further, the study was extended with their variants. The variants’ structure was homology-modelled using the Schrödinger Prime module (Schrödinger LLC, NY, USA).

The first discovered intrinsic beta-lactamase of , OXA-51, had a binding energy value of −40.984 kcal mol, whereas other OXA-51 variants, such as OXA-64, OXA-110 and OXA-111, have values of −60.638, –66.756 and −67.751 kcal mol, respectively. The free energy values of OXA-51 variants produced better results than those of other groups.

Imipenem and meropenem showed MIC values of 2 and 8 µg ml, respectively against OXA-51 in earlier studies, indicating that these are the most effective drugs for treatment of infection. According to our results, OXA-51 is an active enzyme that shows better interactions and is capable of hydrolyzing carbapenems. When correlating the hydrogen-bonding interaction with MIC values, the predicted results are in good agreement and might provide initial insights into performing similar studies related to OXA variants or other antibiotic–enzyme-based studies.

Funding
This study was supported by the:
  • Jeyakanthan Jeyaraman , DST Indo Taiwan project , (Award GITA/DST/TWN/P-86/2019 Dated: 04/03/2020)
  • Jeyakanthan Jeyaraman , MHRD-RUSA 2.0, New Delhi , (Award F.24-51/2014-U, Policy (TNMulti-Gen), Dept. of Edn. Govt. of India, Dt. 09.10.2018)
  • Jeyakanthan Jeyaraman , Department of Science and Technology, Ministry of Science and Technology (IN) , (Award File No. EMR/2016/000498 dated: 26.09.2016)
  • Jeyakanthan Jeyaraman , Research Grants Council, University Grants Committee (HK) , (Award UGC-RA-2016-18-OB-AM-7124 dated: 18.04.2016)
  • Jeyakanthan Jeyaraman , DST – Promotion of University Research and Scientific Excellence (PURSE) , (Award No. SR/PURSE Phase2/38)
  • , DST – FIST , (Award SR/FST/LSI-667/2016)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001233
2020-08-10
2020-09-20
Loading full text...

Full text loading...

References

  1. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care 2016; 20:221 [CrossRef][PubMed]
    [Google Scholar]
  2. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH, Eric W. Inhaled antibiotics for Gram-negative respiratory infections. Clin Microbiol Rev 2016; 29:581–632 [CrossRef][PubMed]
    [Google Scholar]
  3. Fournier PE, Richet H, Hervé R. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692–699 [CrossRef][PubMed]
    [Google Scholar]
  4. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25:465–472 [CrossRef][PubMed]
    [Google Scholar]
  5. van den Akker F, Bonomo RA. Exploring additional dimensions of complexity in inhibitor design for serine β-lactamases: mechanistic and intra- and inter-molecular chemistry approaches. Front Microbiol 2018; 9:622 [CrossRef][PubMed]
    [Google Scholar]
  6. Kobs VC, Ferreira JA, Bobrowicz TA, Ferreira LE, Deglmann RC et al. The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting. Rev Soc Bras Med Trop 2016; 49:433–440 [CrossRef][PubMed]
    [Google Scholar]
  7. Egan AJF, Cleverley RM, Peters K, Lewis RJ, Vollmer W. Regulation of bacterial cell wall growth. Febs J 2017; 284:851–867 [CrossRef][PubMed]
    [Google Scholar]
  8. Frère JM. Beta-Lactamases and bacterial resistance to antibiotics. Mol Microbiol 1995; 16:385–395 [CrossRef][PubMed]
    [Google Scholar]
  9. Lee W, McDonough MA, Kotra L, Li ZH, Silvaggi NR et al. A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A 2001; 98:1427–1431 [CrossRef][PubMed]
    [Google Scholar]
  10. Ambler RP. The structure of beta-lactamases. Phil Trans R Soc London B Biol Sci 1980; 289:321–331
    [Google Scholar]
  11. Majiduddin FK, Materon IC, Timothy P. Amino Acid Residues that contribute to substrate speificity of Class A Beta-lactamase SME - 1. Int J Med Microbiol 2002; 292:127–137
    [Google Scholar]
  12. Lohans CT, Freeman EI, Groesen Evan, Tooke CL, Hinchliffe P et al. Mechanistic insights into β-Lactamase-Catalysed carbapenem degradation through product characterisation. Sci Rep 2019; 9:13608 [CrossRef][PubMed]
    [Google Scholar]
  13. Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M et al. Antimicrobial-Resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. J Antimicrob Chemother 2019; 74:645–653 [CrossRef][PubMed]
    [Google Scholar]
  14. Vila J, Pachón J, Jerónimo P. Therapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008; 9:587–599 [CrossRef][PubMed]
    [Google Scholar]
  15. Smith CA, Antunes NT, Stewart NK, Toth M, Kumarasiri M et al. Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii . Chem Biol 2013; 20:1107–1115 [CrossRef][PubMed]
    [Google Scholar]
  16. Evans BA, Amyes SGB. Oxa β-lactamases. Clin Microbiol Rev 2014; 27:241–263 [CrossRef][PubMed]
    [Google Scholar]
  17. Sgrignani J, Grazioso G, De Amici M, Jacopo S, Giovanni G. Insight into the mechanism of hydrolysis of meropenem by OXA-23 Serine-β-lactamase gained by quantum mechanics/molecular mechanics calculations. Biochemistry 2016; 55:5191–5200 [CrossRef][PubMed]
    [Google Scholar]
  18. Choubey SK, Prabhu D, Nachiappan M, Biswal J, Jeyakanthan J. Molecular modeling, dynamics studies and density functional theory approaches to identify potential inhibitors of SIRT4 protein from Homo sapiens : a novel target for the treatment of type 2 diabetes. J Biomol Struct Dyn 2017; 35:3316–3329 [CrossRef][PubMed]
    [Google Scholar]
  19. Tremblay LW, Xu H, Blanchard JS, Lee WT, Hua X, John SB. Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants. Biochemistry 2010; 49:9685–9687 [CrossRef][PubMed]
    [Google Scholar]
  20. Kalp M, Sheri A, Buynak JD, Bethel CR, Bonomo RA et al. Efficient inhibition of class A and class D beta-lactamases by Michaelis complexes. J Biol Chem 2007; 282:21588–21591 [CrossRef][PubMed]
    [Google Scholar]
  21. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN et al. The protein data bank. Nucleic Acids Res 2000; 28:235–242 [CrossRef][PubMed]
    [Google Scholar]
  22. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013; 27:221–234 [CrossRef][PubMed]
    [Google Scholar]
  23. Banks JL, Beard HS, Cao Y, Cho AE, Damm W et al. Integrated modeling program, applied chemical theory (impact). J Comput Chem 2005; 26:1752–1780 [CrossRef][PubMed]
    [Google Scholar]
  24. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46:D1074–D1082 [CrossRef][PubMed]
    [Google Scholar]
  25. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47:1739–1749 [CrossRef][PubMed]
    [Google Scholar]
  26. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–1612 [CrossRef][PubMed]
    [Google Scholar]
  27. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel 1995; 8:127–134 [CrossRef]
    [Google Scholar]
  28. Madeira F, Park Ymi, Lee J, Buso N, Gur T et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 2019; 47:W636–W641 [CrossRef]
    [Google Scholar]
  29. Yuiko T, Dimitri C, Philip W, Benjamin E. Evolution towards increased carbapenemase activity in the OXA-51-like beta-lactamases of Acinetobacter baumannii . In European congress of Clinical Microbiology and Infectious Diseases Madrid, Spain; 2018
    [Google Scholar]
  30. Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B et al. A hierarchical approach to all-atom protein loop prediction. Proteins 2004; 55:351–367 [CrossRef][PubMed]
    [Google Scholar]
  31. Lyne PD, Lamb ML, Saeh JC. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 2006; 49:4805–4808 [CrossRef]
    [Google Scholar]
  32. Staude MW, Leonard DA, Peng JW. Expanded substrate activity of OXA-24/40 in carbapenem-resistant Acinetobacter baumannii involves enhanced binding loop flexibility. Biochemistry 2016; 55:6535–6544 [CrossRef][PubMed]
    [Google Scholar]
  33. Toth M, Antunes NT, Stewart NK, Frase H, Bhattacharya M et al. Class D β-lactamases do exist in Gram-positive bacteria. Nat Chem Biol 2016; 12:9–14 [CrossRef][PubMed]
    [Google Scholar]
  34. Schneider KD, Ortega CJ, Renck NA, Bonomo RA, Powers RA et al. Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J Mol Biol 2011; 406:583–594 [CrossRef][PubMed]
    [Google Scholar]
  35. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G et al. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii . Antimicrob Agents Chemother 2013; 57:2121–2126 [CrossRef]
    [Google Scholar]
  36. Smith CA, Antunes NT, Stewart NK, Frase H, Toth M et al. Structural basis for enhancement of carbapenemase activity in the OXA-51 family of class D β-lactamases. ACS Chem Biol 2015; 10:1791–1796 [CrossRef]
    [Google Scholar]
  37. El-Gamal MI, Kim SJ, Oh C-H. Synthesis and in vitro antibacterial activity of new meropenem analogs. J Antibiot 2011; 64:687–688 [CrossRef][PubMed]
    [Google Scholar]
  38. Kevin JB, Edmond C, Xu H, Ron OD, Michael PE. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the ACM/IEEE conference on Supercomputing (SC06), November 11-17 Tampa, Florida: 2006
    [Google Scholar]
  39. Verma V, Testero SA, Amini K, Wei W, Liu J et al. Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from Acinetobacter baumannii . J Biol Chem 2011; 286:37292–37303 [CrossRef][PubMed]
    [Google Scholar]
  40. Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H et al. Class D β-lactamases: are they all carbapenemases?. Antimicrob Agents Chemother 2014; 58:2119–2125 [CrossRef]
    [Google Scholar]
  41. Tiwari V, Nagpal I, Subbarao N, Moganty RR. In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics. J Mol Model 2012; 18:3351–3361 [CrossRef][PubMed]
    [Google Scholar]
  42. Smith PW, Zuccotto F, Bates RH, Martinez-Martinez MS, Read KD et al. Pharmacokinetics of β-lactam antibiotics: clues from the past to help discover long-acting oral drugs in the future. ACS Infect Dis 2018; 4:1439–1447 [CrossRef][PubMed]
    [Google Scholar]
  43. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G et al. OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii . Antimicrob Agents Chemother 2013; 57:2121–2126 [CrossRef]
    [Google Scholar]
  44. Tonge PJ. Drug-Target kinetics in drug discovery. ACS Chem Neurosci 2018; 9:29–39 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001233
Loading
/content/journal/jmm/10.1099/jmm.0.001233
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error